Tapentadol (Nucynta): Uses, How It Works and Safety

Tapentadol is a prescription opioid that a doctor may offer when pain is severe and other treatments have not been enough. In the US it is sold as Nucynta and Nucynta ER, and it sits in Schedule II, the strictest category for medicines that still have an accepted medical use. This guide explains what tapentadol is used for, what makes it different from other opioids, which strengths are actually approved in the US, and the safety steps every patient and household should know.

Most pages about tapentadol either list side effects without context or dive into pharmacology written for clinicians. Here you will find the plain-language middle ground, built on the FDA prescribing information and other US public-health sources, plus the 2025 FDA labeling changes that many older pages still miss.

What is tapentadol?

Tapentadol is a centrally acting pain reliever developed by the German company Grünenthal. The FDA approved it on November 20, 2008, and the DEA placed it in Schedule II the following year, stating in the 2009 Federal Register final rule that it shares substantial pharmacological effects and abuse potential with morphine, oxycodone and hydromorphone. An extended-release version followed in 2011, according to a 2024 review in Cureus.

MedlinePlus describes tapentadol simply as an opioid (narcotic) analgesic that changes the way the brain and nervous system respond to pain. That is accurate, but it leaves out the second half of how the drug works.

How tapentadol works: two actions in one molecule

Tapentadol relieves pain in two ways at once:

• Mu-opioid receptor agonism. Like morphine or oxycodone, it switches on opioid receptors in the brain and spinal cord that dampen pain signals. This is also the action behind its risks: euphoria, dependence and slowed breathing.
• Norepinephrine reuptake inhibition. It keeps more norepinephrine available in the spinal cord, which strengthens the body’s own pain-dampening pathways. This is one reason it has been studied, and approved in ER form, for diabetic nerve pain.

Review authors note that tapentadol tends to cause fewer gastrointestinal side effects, such as constipation, than pure opioid agonists at comparable pain relief (Cureus, 2024). That does not make it a “mild” opioid. Its addiction, overdose and breathing risks are the same class of risks carried by every Schedule II opioid.

How the body handles it

According to the FDA prescribing information for Nucynta oral solution, about 32% of an oral dose reaches the bloodstream because of extensive first-pass metabolism in the liver. The drug is broken down mainly by glucuronidation, with only small fractions handled by the CYP2C9, CYP2C19 and CYP2D6 enzymes, and about 99% is cleared through the kidneys. Its average half-life is about 4 hours, which is why immediate-release doses are spaced every 4 to 6 hours and the ER tablet is designed for twice-daily use.

What tapentadol is used for in the US

The FDA-approved uses depend on the formulation:

• Nucynta tablets (immediate release): acute pain severe enough to require an opioid in adults, when other treatments are inadequate (FDA label, Nucynta tablets).
• Nucynta oral solution: the same acute-pain use in adults and in children 6 years and older who weigh at least 16 kg, for no more than 3 days in children (FDA label, oral solution).
• Nucynta ER (extended release): pain severe enough to require daily, around-the-clock, long-term opioid treatment, and neuropathic pain from diabetic peripheral neuropathy, in adults for whom other options are inadequate. It is not meant for as-needed use (FDA label, Nucynta ER).

The CDC’s 2022 opioid prescribing guideline asks clinicians to try non-opioid medicines and non-drug treatments first, to start with immediate-release rather than extended-release opioids, and to prescribe only the amount needed for the expected length of severe acute pain. Expect your prescriber to follow that approach with tapentadol too.

Approved US forms and strengths

Knowing the real US products helps you spot a problem. These are the strengths in the FDA labels:

Product	Approved strengths	How it is taken	Label maximums
Nucynta (immediate-release tablets)	50 mg, 75 mg, 100 mg film-coated tablets	Every 4 to 6 hours as needed	Doses above 700 mg on day 1 and 600 mg a day after that have not been studied and are not recommended
Nucynta oral solution	20 mg/mL	Measured with an oral syringe, every 4 to 6 hours as needed	Same adult limits as the tablets; separate weight-based limits for children
Nucynta ER (extended-release tablets)	50, 100, 150, 200 and 250 mg	About every 12 hours, swallowed whole	Do not exceed 500 mg a day

Your prescriber chooses the dose and adjusts it based on pain relief and side effects; the table only shows what the FDA labels allow. Tablets with unfamiliar brand names, or strengths that do not appear on this list, are not US-approved tapentadol products. That matters because the DEA reports that 6 out of 10 fentanyl-laced fake prescription pills it tested in 2022 contained a potentially lethal dose. The DEA’s advice is blunt: never take a pill that was not prescribed directly to you.

The ER tablet carries its own warning. The label states that crushing, chewing or dissolving Nucynta ER releases the drug all at once, which can cause a fatal overdose. Swallow it whole, one tablet at a time.

Tapentadol safety: the FDA boxed warning

Every tapentadol product carries a boxed warning, the FDA’s most serious label warning. It covers:

• Addiction, abuse and misuse, which can happen even at prescribed doses.
• Life-threatening respiratory depression (slowed or stopped breathing), most likely in the first 24 to 72 hours and after a dose increase, as MedlinePlus explains.
• Accidental ingestion, especially by children, which can be fatal.
• Risks with benzodiazepines and other central nervous system depressants, including alcohol, which can cause profound sedation, breathing problems, coma and death.
• Neonatal opioid withdrawal syndrome when used for long periods during pregnancy.
• The Opioid Analgesic REMS, an FDA-required safety program that includes prescriber education and patient counseling.
• Medication errors with the oral solution, where confusing mg and mL can lead to overdose.

What changed in 2025

On July 31, 2025, the FDA announced required safety labeling changes for all opioid pain medicines to better describe the risks of long-term use. The updates stress that higher doses carry higher overdose risk, that serious harms persist throughout treatment, and that extended-release opioids such as Nucynta ER should be used only when other options, including immediate-release opioids, are inadequate. They also add warnings about combining opioids with gabapentinoids (gabapentin and pregabalin), a reminder not to stop opioids abruptly in people who are physically dependent, and more information on overdose-reversal medicines. In one FDA-required study, about 22% of patients newly met criteria for misuse over 12 months of opioid treatment.

Common side effects

In adult clinical trials listed in the FDA label, the most common side effects of immediate-release tapentadol were:

Side effect	Tapentadol	Placebo
Nausea	30%	13%
Dizziness	24%	8%
Vomiting	18%	4%
Sleepiness (somnolence)	15%	3%
Constipation	8%	3%
Itching	5%	1%

MedlinePlus also lists headache, dry mouth, tiredness, anxiety, trouble sleeping and a sudden feeling of warmth. Because tapentadol can make you drowsy or dizzy, do not drive or use machinery until you know how it affects you, and get up slowly from lying down.

Serious risks beyond the boxed warning

Serotonin syndrome

Because tapentadol affects norepinephrine, the FDA label warns that it can contribute to serotonin syndrome, a potentially life-threatening reaction, when combined with other serotonergic medicines such as many antidepressants or migraine triptans. It can happen even within the recommended dose range. Warning signs include agitation, hallucinations, fever, sweating, shivering, fast heartbeat, severe muscle stiffness or twitching and loss of coordination. Tapentadol must not be taken with an MAO inhibitor or within 14 days of stopping one, and Mayo Clinic also flags linezolid and methylene blue as medicines that generally should not be combined with it.

Seizures

Tapentadol may increase seizure frequency in people with a seizure disorder. Tell your prescriber about any history of seizures or head injury.

Adrenal insufficiency

Opioids can suppress the adrenal glands, most often after more than a month of use. Symptoms are vague, such as nausea, vomiting, loss of appetite, weakness, dizziness and low blood pressure, so mention them if they appear.

Liver and kidney problems, and older adults

The FDA label recommends a reduced starting dose and longer gaps between doses for moderate liver impairment, and it does not recommend tapentadol for severe liver impairment or severe kidney impairment. Adults 65 and older may be more sensitive to the drug, so prescribers generally start at the low end of the range and increase slowly.

Pregnancy, breastfeeding and fertility

Regular use during pregnancy can cause life-threatening withdrawal in the newborn. Talk with your provider before using tapentadol while breastfeeding, and know that long-term opioid use may reduce fertility in both men and women (MedlinePlus).

Interactions to know about

• Alcohol: do not drink alcohol while taking tapentadol. Together they deepen sedation and slow breathing.
• Benzodiazepines and sleep medicines: medicines such as alprazolam, lorazepam or diazepam, and sleep aids such as zolpidem, add to the risk of dangerous sedation. The CDC guideline asks prescribers to use particular caution with this combination.
• Gabapentin and pregabalin: added to opioid labels in 2025 as CNS depressants that raise the risk of breathing problems.
• Other opioids, muscle relaxants and sedating antihistamines: also add to sedation.
• Antidepressants, triptans, St. John’s wort and tryptophan: can raise the risk of serotonin syndrome.
• MAO inhibitors: do not combine, and wait 14 days after stopping one.

Keep an up-to-date list of every prescription, over-the-counter medicine and supplement you take, and show it to each prescriber and pharmacist.

Tolerance, dependence and stopping tapentadol

With regular use, the body adapts to tapentadol. Stopping suddenly can cause withdrawal symptoms such as anxiety, sweating, nausea, diarrhea and a fast heartbeat. The FDA warns against abrupt discontinuation or rapid dose reduction in people who are physically dependent. If you want to stop or lower your dose, ask your prescriber to plan a gradual reduction with you rather than doing it on your own.

Dependence is not the same as addiction, but both are possible. Signs that use is becoming a problem include taking more than prescribed, running out early, craving the medicine or using it for reasons other than pain. If that sounds familiar, the SAMHSA National Helpline (1-800-662-4357) offers free, confidential treatment referrals 24 hours a day.

Keep naloxone at home

Naloxone reverses an opioid overdose. In March 2023 the FDA approved Narcan 4 mg nasal spray for over-the-counter sale, so you can buy it without a prescription at many pharmacies and stores. The CDC guideline recommends that clinicians offer naloxone to patients at increased risk of overdose. Anyone who lives with or cares for a person taking tapentadol should know where the naloxone is kept and how to use it.

Safe storage and disposal

Store tapentadol in its original container at room temperature, away from heat and moisture, and keep it locked or out of sight and reach of children, teenagers, visitors and pets. Count your tablets so you notice if any go missing.

When you no longer need it, the FDA says a drug take-back location or a prepaid mail-back envelope is the best option. Tapentadol is on the FDA flush list, so if no take-back option is readily available, flushing it is acceptable to prevent accidental ingestion.

Questions to ask your prescriber

• Why is tapentadol a better fit for my pain than non-opioid options or a different opioid?
• How long do you expect me to need it, and what is the plan for stopping?
• Is the immediate-release form enough, or do I need Nucynta ER? Why?
• Could any of my current medicines, especially antidepressants, sleep aids, anxiety medicines or gabapentin, interact with it?
• Should I keep naloxone at home, and who in my household should learn to use it?
• What side effects should make me call you, and which ones mean I should call 911?
• Do my liver, kidney or breathing conditions change the dose I should take?

Frequently asked questions

Is tapentadol a narcotic?

Yes. Tapentadol is an opioid, often called a narcotic, and the DEA classifies it as a Schedule II controlled substance because its abuse potential is similar to morphine, oxycodone and hydromorphone. In the US it requires a valid prescription.

What is the brand name of tapentadol in the US?

Tapentadol is sold in the US as Nucynta (immediate-release tablets and oral solution) and Nucynta ER (extended-release tablets).

Is tapentadol used for nerve pain?

Nucynta ER is FDA-approved for neuropathic pain from diabetic peripheral neuropathy in adults whose pain is severe enough to need daily, around-the-clock opioid treatment and for whom other options are inadequate. The immediate-release forms are approved for acute pain.

How long does tapentadol last?

Tapentadol has an average half-life of about 4 hours. Immediate-release doses are taken every 4 to 6 hours as needed, while Nucynta ER tablets are taken about every 12 hours.

Can I drink alcohol while taking tapentadol?

No. Alcohol adds to the sedating and breathing-slowing effects of tapentadol and can lead to overdose. Avoid alcohol completely while taking it.

Related guides

• Modafinil Explained: Uses, How It Works and Safety

Sources

1. FDA. Nucynta (tapentadol) tablets prescribing information.
2. FDA. Nucynta ER (tapentadol) extended-release tablets prescribing information.
3. FDA. Nucynta (tapentadol) oral solution prescribing information, revised 07/2023.
4. MedlinePlus. Tapentadol drug information.
5. Mayo Clinic. Tapentadol (oral route).
6. Federal Register. Schedules of Controlled Substances: Placement of Tapentadol Into Schedule II (May 21, 2009).
7. FDA. FDA requiring opioid pain medicine manufacturers to update prescribing information regarding long-term use (July 31, 2025).
8. CDC. Clinical Practice Guideline for Prescribing Opioids for Pain, 2022: recommendations.
9. FDA. FDA approves first over-the-counter naloxone nasal spray (March 29, 2023).
10. FDA. Drug disposal: FDA’s flush list for certain medicines.
11. DEA. Laboratory testing reveals 6 out of 10 fentanyl-laced fake prescription pills contain a potentially lethal dose.
12. Zavaleta-Monestel E, et al. Tapentadol: a comprehensive review of its role in pain management. Cureus. 2024;16(11):e74307.